Danish Alkai--Abeyo Company Beijing Representative Office

Primary objective: To confirm the efficacy of dust mite allergen sublingual tablets compared with placebo for the treatment of nasal symptoms of dust mite allergic rhinitis as measured during the EEC at Week 24. Key secondary objectives: To confirm the efficacy of dust mite allergen sublingual tablets compared with placebo for the treatment of dust mite allergic rhinitis with or without conjunctivitis as measured during the EEC at Week 24. Safety objective: To evaluate the safety and tolerability of dust mite allergen sublingual tablets compared with placebo during the 24-week treatment period.

To evaluate the safety and tolerability of 12 SQ-HDM doses of SQ dust mite allergen sublingual tablets compared with placebo in Chinese adult subjects with dust mite allergic rhinitis with or without asthma.